Metabasis Therapeutics Inc.
11119 North Torrey Pines Road
La Jolla,
CA 92037
United States - Map
Phone: 858-587-2770
Fax: 858-458-3504
Web Site: http://www.mbasis.com
| Metabasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel drugs targeting the liver and liver pathways. Its product pipeline includes clinical-stage product candidates and advanced discovery programs for the treatment of metabolic diseases, such as diabetes and hyperlipidemia. The companys product candidates under development comprise MB07811, which is in Phase II clinical trials for the treatment of hyperlipidemia; and MB07803, which is in Phase II clinical trials for the treatment of type 2 diabetes. Its metabolic disease advanced discovery programs consist of AMPK, a metabolic disease program focusing on the development of drug candidates for the treatment of type 2 diabetes and other metabolic diseases; Glucagon Antagonist, a program focusing on identifying orally bioavailable glucagon antagonists for the treatment of type 2 diabetes; and TRß agonist, a second-generation program to identify drug candidates for the treatment of hyperlipidemia. It has collaborative research and development agreements with Roche; Merck & Co.; Idenix Pharmaceuticals, Inc.; Daiichi Sankyo Company, Ltd.; Valeant Pharmaceuticals International; and Schering Corporation. The company was founded in 1997 and is based in La Jolla, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. David F. Hale , 59
Exec. Chairman, Acting Principal Exec. Officer, Chairman of Compensation Committee and Member of Audit Committee |
$
147.00K | N/A | Dr. Paul Laikind Ph.D., 53
Co-Founder |
N/A
| N/A | Mr. Tran B. Nguyen M.B.A., 35
Chief Financial Officer, Principal Accounting Officer, VP of Fin., Treasurer and Corp. Sec. |
N/A
| N/A | Dr. Scott J. Hecker Ph.D.,
VP of Chemistry |
N/A
| N/A | Dr. R. Wayne Frost Pharm. D., JD, 54
VP of Regulatory Affairs & Quality Assurance |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.51% Nasdaq 
Profile
